Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment.

Hyeyeon HongMinjoo ChoChaeyeon LimWon-Mook ChoiDanbi LeeJu Hyun Shim Kang Mo Kim Young Suk Lim Han Chu Lee Jonggi Choi

Published in: Alimentary pharmacology & therapeutics (2023)

NUC-treated patients, especially those on TDF, faced a higher CKD progression risk than untreated patients. Entecavir- and TAF-treated patients had comparable CKD progression risks to untreated patients. No difference was observed between entecavir and TAF in the risk of CKD progression.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
hepatitis b virus
patient reported outcomes
patient reported
smoking cessation
human health